Back to search
FDAFDA · Food and drugs·Recall number D-0645-2020

Ranitidine 150 mg tablets, 24 count bottles, NDC 37808-196-01.

Published January 15, 2020 · Recall initiated: December 26, 2019

Summary

FDA records drug Class II recall D-0645-2020, published January 15, 2020 and initiated December 26, 2019. Recalling firm: AAA Pharmaceutical, Inc.; Status: Terminated; Reported quantity: 34,272 (24-count bottles); Lot: P134458, Sept 2020 P134943, Aug 2020 P135840, Aug, 2020 P136622, April 2021 P136871, April 2021 P137347, April 2021 P137424, April 2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
AAA Pharmaceutical, Inc.
Distributor
Product was distributed to one consignee who may have distributed the product further to their retail stores.
Lot
P134458, Sept 2020 P134943, Aug 2020 P135840, Aug, 2020 P136622, April 2021 P136871, April 2021 P137347, April 2021 P137424, April 2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ranitidine 150 mg tablets, 24 count bottles, NDC 37808-196-01. recalled?

Yes. FDA published recall D-0645-2020 on January 15, 2020. Reported hazard: CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

What should I do if I have this product?

Voluntary: Firm initiated · Letter